Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.935 USD | +0.26% | +1.32% | +36.52% |
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+36.52% | 133M | - | ||
+49.52% | 56.95B | B- | ||
+39.98% | 40.26B | A | ||
-7.53% | 39.32B | B | ||
-4.42% | 28.37B | C | ||
+11.95% | 26.45B | B- | ||
-18.24% | 19.41B | B | ||
+28.93% | 12.54B | C+ | ||
+25.61% | 12.21B | B+ | ||
-1.35% | 12.15B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ATYR Stock
- Ratings aTyr Pharma, Inc.